D. Boral Capital Reaffirms “Buy” Rating for Invivyd (NASDAQ:IVVD)

Invivyd (NASDAQ:IVVD)‘s stock had its “buy” rating reiterated by analysts at D. Boral Capital in a note issued to investors on Thursday,Benzinga reports. They presently have a $9.00 price objective on the stock.

Several other research firms also recently issued reports on IVVD. Morgan Stanley dropped their price objective on Invivyd from $9.50 to $3.55 and set an “overweight” rating on the stock in a report on Wednesday, November 20th. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price target on shares of Invivyd in a report on Monday, February 24th. Four analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Buy” and an average price target of $7.89.

Invivyd Trading Down 0.1 %

NASDAQ IVVD opened at $0.74 on Thursday. The company’s fifty day simple moving average is $0.98 and its 200-day simple moving average is $0.87. The stock has a market cap of $88.28 million, a P/E ratio of -0.38 and a beta of 0.09. Invivyd has a 52 week low of $0.35 and a 52 week high of $4.74.

Invivyd (NASDAQ:IVVD) last posted its quarterly earnings data on Thursday, March 20th. The company reported ($0.15) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.10. The firm had revenue of $13.80 million during the quarter, compared to analysts’ expectations of $13.57 million. On average, research analysts expect that Invivyd will post -1.64 EPS for the current fiscal year.

Insider Activity

In other Invivyd news, Director Terrance Mcguire sold 83,817 shares of Invivyd stock in a transaction on Thursday, December 26th. The shares were sold at an average price of $0.54, for a total value of $45,261.18. Following the completion of the transaction, the director now owns 3,340,520 shares of the company’s stock, valued at $1,803,880.80. The trade was a 2.45 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. In the last ninety days, insiders sold 246,138 shares of company stock worth $120,902. 17.90% of the stock is currently owned by insiders.

Institutional Trading of Invivyd

A number of institutional investors and hedge funds have recently modified their holdings of the business. Mithril II GP LP bought a new stake in shares of Invivyd in the 4th quarter worth approximately $4,981,000. State Street Corp lifted its stake in Invivyd by 3.7% in the third quarter. State Street Corp now owns 1,018,640 shares of the company’s stock valued at $1,039,000 after buying an additional 35,904 shares during the last quarter. Deutsche Bank AG boosted its holdings in shares of Invivyd by 35.2% during the fourth quarter. Deutsche Bank AG now owns 874,406 shares of the company’s stock valued at $385,000 after acquiring an additional 227,463 shares during the period. Two Sigma Investments LP grew its position in shares of Invivyd by 125.3% during the fourth quarter. Two Sigma Investments LP now owns 367,100 shares of the company’s stock worth $163,000 after acquiring an additional 204,188 shares during the last quarter. Finally, Two Sigma Advisers LP increased its holdings in shares of Invivyd by 1,276.5% in the 4th quarter. Two Sigma Advisers LP now owns 304,200 shares of the company’s stock worth $135,000 after acquiring an additional 282,100 shares during the period. 70.36% of the stock is owned by institutional investors and hedge funds.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.